Search
Tractament del CPNM metastàtic EFGR positiu amb inhibidors d’ITK en primera línia: informe d'avaluació de resultats
(2021)
Lung cancer (LC) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of new cases of LC for 2019 was 29,503 cases. LC remains the leading cause of cancer death in Spain in both ...
Voretigen neparvovec per al tractament de la distròfia retinal associada a la mutació RPE65 bial·lèlica
(2021-05-13)
Hereditary retinal dystrophies (HRD) include a group of minority genetic diseases that affect vision. The main cause of this group of pathologies is germline mutations described in more than 260 genes, including the gene ...
Tractament del CPNM metastàtic en primera i segona línia amb immunoteràpia: informe d'avaluació de resultats
(2021)
Lung cancer (LC) is one of the most frequently diagnosed cancers worldwide. In Spain, the estimated incidence of LC for 2019 was 29,503 new cases. LC remains the leading cause of cancer death in Spain in both sexes, with ...
Upadacitinib per al tractament de l’artritis reumatoide de moderada a greu
(2021-03-03)
Rheumatoid arthritis (RA) is an inflammatory disease of autoimmune etiology characterized by chronic inflammation of the synovial membrane, which leads to the progressive destruction of joint structures. Typical symptoms ...
Patiròmer i ciclosilicat de sodi i zirconi per al tractament de la hiperpotassèmia
(2021-05-06)
Serum potassium levels (K-S) are normally maintained within narrow limits (3.5-5.0 mmol / L) by multiple mechanisms. Such strict regulation is essential for numerous cellular processes. Imbalances in potassium (K) homeostasis ...
Burosumab per al tractament de la hipofosfatèmia congènita
(2021-01-21)
X-linked hypophosphatemia (HLX) is a dominant, chronic, and debilitating inherited disease caused by inactivating mutations in the PHEX gene (Phosphate-regulating gene with homologies to endopeptidases on the X chromosome). ...